



Advanced Information

LATEST NEWS FROM GNOSIS



advanced biotech



SPECIAL EDITION

MYTHOCONDRO[®]

The Non-Animal Chondroitin Sulfate

Vegetarian Chondroitin Sulfate: Prof. Volpi marks the turning point with Mythocondro[®]

Nicola Volpi, Associate Professor of Biochemistry at the University of Modena and Reggio Emilia (Italy) and eminent expert of Chondroitin Sulfate (CS), has recently led a group of scientists in the human evaluation of the bioavailability and pharmacokinetic profile of a new formulation in tablets of the Non-Animal, fermentation-derived Chondroitin Sulfate Mythocondro[®] compared with the animal Chondroitin Sulfate.

The new study was centered on the evaluation of how the chondroitin sulfation pattern, particularly in position 6 of the disaccharide chain (Δ Di6S), and the charge density of Mythocondro[®], may influence the capacity of CS to interact with various extracellular molecules and allow exerting more pronounced chondroprotective effects than a CS of extractive origin, as already demonstrated in an animal model study.

[READ MORE](#) →



FOCUS ON:

The advantages of Mythocondro[®] versus Animal CS

Mythocondro[®] represents the evolution of Chondroitin Sulfate and promises to completely change the global CS industry, as it solves any concern related to the production origin and the possible presence of transmissible infective agents, contaminations and adulterations, which are typical of animal-derived raw materials.

[WATCH THE CHART](#) →



MYTHOCONDRO[®]
The Non-Animal Chondroitin Sulfate

- No Allergens
- No GMO
- Vegan
- Vegetarian

gnoSIS

MYTHOCONDRO[®]
THE NON-ANIMAL CS PRODUCT BY A NATURAL FERMENTATION PROCESS

Incoming Events

Mythocondro[®], the Non-Animal CS: efficacy at 600 mg


Knee Osteoarthritis (OA) represents an important cause of disability among adults of 60 years of age or more.

Recently, a randomized, double blind, placebo-controlled clinical trial has been conducted on humans to assess the **efficacy and safety** of a low-dose of non-animal CS - as Mythocondro[®] - in treating subjects with knee OA.

The study involved 60 caucasian subjects, males and females, overweight (BMI > 25 kg/m²), aged 40-74, with mobility impairment, joint discomfort or established moderate knee OA (classification 1-3 according to Kellgren and Lawrence system for classification of knee OA), pain intensity measured using the Visual Analogue Scale (VAS) with a value of 40-70 mm, Lequesne Index of 6-10.

They were divided into two groups: 30 of them received one tablet of 600 mg of Mythocondro[®] each day for 12 weeks, the other 30 were provided with a placebo.

[READ MORE ABOUT THE STUDY](#) →



September 6th - 9th



Dallas, Texas (USA)
Booth # 26



September 11th - 12th



Singapore
Booth # M20



October 9th - 11th



Madrid, Spain
Booth # 5A20



November 8th - 9th



Las Vegas, USA
Booth # 3937



These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. This is a business-to-business information intended for food and supplement producers, and is not intended for the final consumer. Manufacturers should check local regulatory status of any claims according to the intended use of their products.

join our network, follow us on our social:

